As reported by Gene Quinn on IPWatchdog.com, for many months we have been hearing about the US government attempts to “reform” health care in the United States, and in the first weekend of December 2009 the US Senate was actually working, as the contentious debate continues. Even a relatively rare Presidential visit to Capitol Hill was scheduled for the afternoon of 6 December 2009, presumably so President Obama can rally the troops for whatever lies ahead. While patent policy has not taken centre stage in these debates, it is hard to ignore the under current that rages through the debates. Health care costs too much, so costs need to be contained. Of course, market initiatives like a national heath insurance market, which would lower premiums for everyone overnight, are not being considered.
- INICIO
-
Genéricos
Novedades
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Investigación
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
-
Biosimilares
Novedades
- FDA approves third ustekinumab biosimilar Pyzchiva
- La FDA aprueba el primer biosimilar de eculizumab, Bkemv, para dos enfermedades raras
- EMA recommends approval of biosimilar bevacizumab Avzivi
- EC biosimilar approvals: Omlyclo, Jubbonti/Wyost, and Pyzchiva
Investigación
- Resultados principales del programa de desarrollo clínico del biosimilar candidato AVT05 golimumab
- Eficacia y seguridad del P043 propuesto (Zerafil) frente al omalizumab de referencia en el asma alérgica
- Tocilizumab and pembrolizumab biosimilar advances for Korean firms
- Unveiling key clinical findings for denosumab biosimilar candidates
- MORE EDITORIAL SECTIONS
- Search
Post your comment